IRF5 and neoplasm: Targeted mRNA nanocarriers encoding IRF5 and IKKβ can effectively reprogram TAMs from an immunosuppressive M2 phenotype to a pro-inflammatory M1 phenotype, thereby promoting an anti-tumor immune response.